Inosine Pranobex
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Inosine Pranobex: From Viral Infections/Immune Deficiency to Osteoarthritis
One-Sentence Summary
Inosine pranobex is an immunomodulatory/antiviral agent historically used in viral infections and immune deficiency states. The TxGNN model predicts it may be effective for Osteoarthritis, but this is currently supported by 0 clinical trials and 0 publications — the prediction rests on the algorithm’s score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not formally documented in this evidence pack; historically used for viral infections and immune deficiency states |
| Predicted New Indication | Osteoarthritis |
| TxGNN Prediction Score | 98.09% |
| Evidence Level | L5 |
| UK Market Status | Not Marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap). Based on the information available in this pack, Inosine pranobex acts as an immunomodulator/antiviral agent, thought to work primarily by enhancing T-cell function and antiviral activity — a profile associated with viral infection and immunodeficiency management, not joint disease.
Osteoarthritis (OA) is pathologically characterised by cartilage degeneration and localised, largely non-immune-driven inflammation. There is no established or literature-supported mechanistic link between immune enhancement/antiviral activity and cartilage repair or OA progression. The evidence pack itself notes that this ranking arises purely from the TxGNN algorithm’s prediction score, with no supporting clinical or preclinical data.
Note for context: within the same prediction batch, a lower-ranked candidate — rheumatoid arthritis (rank 3, score 97.74%) — is supported by one placebo-controlled RCT and multiple open-label/cohort studies (evidence level L2). However, the mechanistic direction there is also contested, since RA typically requires immunosuppression rather than immune stimulation. This is flagged as a separate, better-evidenced candidate that may warrant its own evaluation, but it is not the subject of this report.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
UK Market Information
Inosine pranobex currently holds no marketing authorisation in this jurisdiction (Market status: Not Marketed; Total licenses: 0). No product, dosage form, or approved indication data is available.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: Regulatory warning/contraindication data (TFDA product labelling) is currently unavailable and is flagged as a Blocking data gap — this must be resolved before any safety evaluation (S1 stage) can proceed for this drug.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high, but there is no clinical trial or published literature evidence, and no plausible mechanistic link between the drug’s known immunomodulatory/antiviral activity and osteoarthritis pathology. This is an L5, model-prediction-only candidate with no clinical validation.
To proceed, the following is needed:
- Regulatory warning/contraindication data (TFDA product labelling) — Blocking gap
- Detailed mechanism of action (MOA) data — High-priority gap
- Preclinical or mechanistic studies establishing a plausible link between immune modulation and OA pathophysiology
- Any pilot clinical or observational data in OA populations
- If interest continues in this drug’s repurposing potential, consider separately evaluating rheumatoid arthritis (rank 3), which has substantially stronger existing evidence (L2, 1 RCT)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.